Anthropic Enters Drug Discovery via One-Person Biotech Mithril Medicine; Read as Pre-IPO Signal
kimmonismus · x · 2026-10-28
Anthropic has acquired one-person biotech startup Mithril Medicine and moved into drug discovery: its founder took a potential treatment for a rare muscular dystrophy from idea to promising mouse results in under 18 months, using Claude and 11 external labs. Commentator kimmonismus frames it as: (1) drug discovery will be a major future revenue stream across a 7-billion-person market; (2) the timing was deliberate, announced just before IPO to reassure investors; (3) it shows the world AI matters beyond writing code.
Related event: Anthropic acquires one-person drug startup Mithril Medicine(2 posts)→
More from Companies & People
- Pancake's SF party aims for a Guinness World Record with guests from OpenAI, SpaceX, Nvidia and more — brandon_galang · 2026-10-28
- Critic coins 'cringelabs' to mock giotto_ai's dubious 'sovereign AI' pitch — tensorqt · 2026-10-28
- KHIPU 2027 opens call for workshops, proposals due November 6, 2026 — NandoDF · 2026-10-28
- IEEE Spectrum interviews Google DeepMind's resident philosopher on AI autonomy, safety, human-AI relations — dioscuri · 2026-10-28
- 13 Weeks, 1,701 Posts: OpenAI Sentiment Stuck at 4.9/10 Until Terra Launch — kraios · 2026-10-28
- UvA Amsterdam opens funded AI4Science PhD/Postdoc positions via ELLIS, deadline Oct 31 — windx0303 · 2026-10-28